CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report)'s share price dropped 2.8% on Friday . The stock traded as low as $0.30 and last traded at $0.31. Approximately 1,160,634 shares traded hands during mid-day trading, a decline of 11% from the average daily volume of 1,303,785 shares. The stock had previously closed at $0.32.
CytoDyn Trading Down 2.8%
The firm has a market capitalization of $387.19 million, a PE ratio of -31.00 and a beta of 1.29. The company has a fifty day moving average price of $0.32 and a two-hundred day moving average price of $0.24.
CytoDyn Company Profile
(
Get Free Report)
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CytoDyn, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytoDyn wasn't on the list.
While CytoDyn currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
